US Patent Issued to AMAL THERAPEUTICS on Feb. 4 for "Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine" (Swiss Inventors)

ALEXANDRIA, Va., Feb. 5 -- United States Patent no. 12,214,048, issued on Feb. 4, was assigned to AMAL THERAPEUTICS SA (Geneva).

"Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine" was invented by Madiha Derouazi (Grand-Saconnex, Switzerland) and Elodie Belnoue (Geneva).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides a combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, at least one antigen or antigenic epitope, and a TLR peptide agonist for use in medicine, in particular in the prevention and/or treatment of cancer. Moreover, the p...